申请人:[en]ORION CORPORATION
公开号:WO2022219246A1
公开(公告)日:2022-10-20
The present invention relates to a compound of formula (I) wherein A, Z, L, R1, R2, R3, R4, R5and R33are as defined in claim 1, or a pharmaceutically acceptable salt thereof. The compounds of formula (I) possess utility as inhibitors of TEAD. The compounds are useful as medicaments in the treatment of diseases or conditions wherein inhibition of TEAD is desired, such as cancer and chronic pain.